TA145 Head and neck cancer - cetuximab: review proposal - April 2011
The planned date for review of the above guidance was March 2011.
This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.
Having re-run the search strategy from the original assessment report the Institute has not found any relevant additions to the evidence base that would have a material effect on the guidance. The newly identified evidence is not likely to change the current guidance. NICE will reconsider whether a review is necessary in mid 2015 after the results of NCT00956007 become available. Until that time, we propose that the original guidance should be transferred to the static list.
Topics on the static list may be transferred back to the active list for further consideration if new evidence becomes available that is likely to have a material effect on the last guidance issued.
In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which would suggest that a review would be beneficial. Please see appendix A for a full list of the organisations we have contacted.
This page was last updated: 11 April 2011